Burnett J C
Department of Internal Medicine and Physiology, Mayo Clinic, Rochester, Minnesota 55905.
J Hum Hypertens. 1989 Jun;3 Suppl 1:41-6.
The physiological actions of the atrial peptide system are discussed in relation to its potential role in the aetiology and treatment of hypertension and congestive heart failure (CHF). Atrial natriuretic factor (ANF) exerts marked natriuretic, diuretic and vasodilatory effects and has been demonstrated to reduce blood pressure by several mechanisms, actions which serve to protect the central circulation against volume and pressure overload. It was initially believed that CHF may relate to a deficiency of ANF, but studies of experimentally induced and human CHF have shown elevated levels of circulating ANF, reflecting a compensatory increase in response to reduced cardiac output. In contrast, plasma levels of ANF in hypertension not complicated by CHF are normal and it might be speculated that hypertension reflects an attenuated ANF response to increase cardiac volume and/or pressure. ANF may play an important role in these cardiovascular disease states and, with the availability of synthetic ANF analogues, may also have therapeutic potential.
本文讨论了心房肽系统的生理作用，及其在高血压和充血性心力衰竭（CHF）的病因学和治疗中的潜在作用。心房利钠因子（ANF）具有显著的利钠、利尿和血管舒张作用，已被证明可通过多种机制降低血压，这些作用有助于保护中枢循环免受容量和压力过载的影响。最初认为CHF可能与ANF缺乏有关，但对实验性诱导的和人类CHF的研究表明，循环中的ANF水平升高，这反映了对心输出量减少的代偿性增加。相比之下，未合并CHF的高血压患者血浆ANF水平正常，因此可以推测，高血压反映了ANF对心脏容量和/或压力增加的反应减弱。ANF可能在这些心血管疾病状态中发挥重要作用，并且随着合成ANF类似物的出现，也可能具有治疗潜力。
